Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

Equities research analysts at initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVBGet Free Report) in a research note issued on Wednesday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Trading Up 8.9 %

Shares of NAVB opened at $0.06 on Wednesday. The stock has a 50-day moving average price of $0.06 and a 200-day moving average price of $0.07. Navidea Biopharmaceuticals has a 12-month low of $0.02 and a 12-month high of $0.35.

Navidea Biopharmaceuticals (NYSE:NAVBGet Free Report) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.02) earnings per share for the quarter.

Institutional Investors Weigh In On Navidea Biopharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its stake in shares of Navidea Biopharmaceuticals by 264.5% in the first quarter. Renaissance Technologies LLC now owns 238,133 shares of the company’s stock worth $62,000 after purchasing an additional 172,800 shares during the last quarter. State Street Corp increased its stake in shares of Navidea Biopharmaceuticals by 1,631.1% during the second quarter. State Street Corp now owns 412,743 shares of the company’s stock valued at $38,000 after buying an additional 388,900 shares during the period. Finally, Allred Capital Management LLC raised its holdings in shares of Navidea Biopharmaceuticals by 78.4% during the second quarter. Allred Capital Management LLC now owns 293,838 shares of the company’s stock valued at $27,000 after acquiring an additional 129,100 shares in the last quarter. Hedge funds and other institutional investors own 15.75% of the company’s stock.

About Navidea Biopharmaceuticals

(Get Free Report)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

See Also

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.